StockNews.com assumed coverage on shares of iBio (NYSE:IBIO – Free Report) in a report released on Saturday morning. The brokerage issued a sell rating on the stock.
iBio Stock Up 4.1 %
iBio stock opened at $1.79 on Friday. iBio has a twelve month low of $1.02 and a twelve month high of $26.20. The company has a debt-to-equity ratio of 0.04, a current ratio of 0.91 and a quick ratio of 0.91.
iBio (NYSE:IBIO – Get Free Report) last posted its earnings results on Friday, February 9th. The company reported ($2.42) EPS for the quarter.
iBio Company Profile
iBio, Inc, a biotechnology company, engages in the development of precision antibodies in the United States. It offers IBIO-100, a preclinical anti-fibrotic program for the treatment of systemic scleroderma and idiopathic pulmonary fibrosis; and EngageTx platform, which provides an optimized CD3 T-cell engager antibody panel.
Further Reading
- Five stocks we like better than iBio
- The Significance of a Trillion-Dollar Market Cap Goes Beyond a Number
- It’s Time to Buy Into the Super Micro Computer Stock Implosion
- High Flyers: 3 Natural Gas Stocks for March 2022
- Merger or Not, Albertson’s Companies is a Good Buy
- Unveiling The Power Of VWAP: A Key Indicator For Traders
- 3 Cheap Stocks That Shouldn’t Be So
Receive News & Ratings for iBio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for iBio and related companies with MarketBeat.com's FREE daily email newsletter.
